ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Results of Operations and Financial Condition

Item 2.02.

On March 21, 2017, ARCA biopharma, Inc. (ARCA) issued a press
release reporting financial results for the year ended December
31, 2016.

The press release is attached hereto as Exhibit 99.1, which is
furnished under Item 2.02 of this report and shall not be deemed
to be filed for purposes of Section 18 of the Securities Exchange
Act of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or
the Exchange Act, regardless of any general incorporation
language in such filing.

Section 9 Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

About ARCA biopharma, Inc. (NASDAQ:ABIO)

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

ARCA biopharma, Inc. (NASDAQ:ABIO) Recent Trading Information

ARCA biopharma, Inc. (NASDAQ:ABIO) closed its last trading session up +0.05 at 2.50 with 27,082 shares trading hands.